Krystal Biotech (KRYS)
(Delayed Data from NSDQ)
$201.58 USD
+4.06 (2.06%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $201.56 -0.02 (-0.01%) 7:58 PM ET
1-Strong Buy of 5 1
F Value C Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Krystal Biotech, Inc. [KRYS]
Reports for Purchase
Showing records 1 - 20 ( 68 total )
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
ARVO Insights; HSV-1 Gene Therapy Approach Shows Eye-Opening Potential for Posterior Eye Delivery
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Pipeline Expansion and VYJUVEK Uptake Remain Focus; Multiple Data Readouts by YE24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Oncology Program Advances As First Patient Dosed in Inhaled KB707 Study in Lung Malignancies
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
VYJUVEK Ends 2023 With a Bang; Vibrant Pipeline Pushes Forward; Price Target Increased to $200
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KRYS 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Momentum Across Pipeline Builds; Global VYJUVEK Launch Plans Progressing On Track
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; Nice First Steps For VYJUVEK; Plethora of Trials Supports Krystal's Advancement
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
HSV Expertise and Cytokine Targeting Lead Krystal to Oncology
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
KB407's Phase 1 CORAL-1/US Trial Launches With First CF Patient Dosed; Initial Data Expected in 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
The Time For (Wound) Healing Has Come; VYJUVEK Approved as First DEB Rx; PT Upped to $139
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; Commercial Preparation Activities Ramp Up Ahead of Imminent B-VEC PDUFA
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Seen at ARVO; B-VEC Extends Therapeutic Benefit to Ocular Complications from DEB
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
KB301 Final Cohort Begins in PEARL-1 For Aging Skin; Expecting VYJUVEK Approval Shortly
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
2022 Results; Pipeline Firing on All Cylinders; B-VEC PDUFA Date of May 19, 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Minor Logistical Request Pushes B-VEC PDUFA to May 19, 2023; We Don''t Foresee Any Further Delay
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Looking Good Today, and 9 Months Later Too; PEARL-1 Durability Results Highlight Aesthetic Benefit of KB301
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Eyes On February PDUFA and Making Real Difference In Patients; Target Upped to $119
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BLA Fully in FDA Hands; February 17, 2023, PDUFA Date
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; Prepping for VYJUVEK Hitting Market; Pipeline Hitting Nice Stride
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J